Skip to main content
. Author manuscript; available in PMC: 2017 Apr 1.
Published in final edited form as: Nanomedicine. 2015 Dec 2;12(3):759–770. doi: 10.1016/j.nano.2015.11.007

Figure 2. Inactivated PR8/RSV HA-F262-276 immunization induces RSV neutralizing antibodies without compromising virus immunogenicity.

Figure 2

Mice (n = 5) were immunized intramuscularly with 10 μg or 2 μg of inactivated PR8/RSV HA-F262-276 virus alone or mixed with alum or 2 μg of inactivated PR8 WT virus or 2 μg of FI-RSV in alum. Serum samples were obtained at 3 weeks after boost. IgG (A), IgG1 (B), and IgG2a (C) antibodies specific for RSV F protein in serum. ELISA was performed for F protein-specific serum antibodies using serially diluted serum samples. (D) Ratios of IgG2a/IgG1 isotype antibodies specific for RSV F protein. (E) RSV neutralization titers. The dashed lines denote limits of detection (a titer of 8). (F) Hemagglutination inhibition (HI) titers. HI titers were evaluated by standard methods using 4 HA units of inactivated A/PR8 virus and 1% chicken red blood cells. Error bars indicate mean ± SEM. n.d., not determined.